Literature DB >> 15896728

Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein.

Li-Yu Tsai1, Shih-Men Tsai, Su-Chen Lee, Shu-Fen Liu.   

Abstract

INTRODUCTION: Multiple myeloma is a malignant immunoproliferative disorder with lipoprotein abnormalities. We report a case of falsely low concentrations of LDL-cholesterol (LDL-C) and artifactural undetectable HDL-cholesterol (HDL-C) as measured with direct methods in a patient of multiple myeloma with IgGkappa monoclonal gammapathy and significant hyperlipidemia. CASE REPORT: The patient had HDL-C and LDL-C concentrations in the 0.63-0.71 mmol/l and 2.22-2.36 mmol/l ranges, respectively, as measured by a traditional semi-quantitative electrophoresis method. The observation of falsely low concentrations of LDL-C and artifactural undetectable HDL-C might result in the mismanagement of patients of multiple myeloma with monoclonal gammapathy, because the LDL-C and HDL-C concentrations are positive and negative risk factors of cardiovascular diseases.
CONCLUSIONS: Care must be taken when using the homogenous method for direct measurement of LDL-cholesterol and HDL-cholesterol in patients of multiple myeloma with monoclonal paraprotein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896728     DOI: 10.1016/j.cccn.2005.02.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study.

Authors:  Peter Penson; D Leann Long; George Howard; Virginia J Howard; Steven R Jones; Seth S Martin; Dimitri P Mikhailidis; Paul Muntner; Manfredi Rizzo; Daniel J Rader; Monika M Safford; Amirhossein Sahebkar; Peter P Toth; Maciej Banach
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

2.  Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: results from the Framingham Offspring Study.

Authors:  Seiko Otokozawa; Masumi Ai; Bela F Asztalos; Charles C White; Serkalem Demissie-Banjaw; L Adrienne Cupples; Katsuyuki Nakajima; Peter W F Wilson; Ernst J Schaefer
Journal:  Atherosclerosis       Date:  2010-03-09       Impact factor: 5.162

3.  A Modern Approach to Dyslipidemia.

Authors:  Amanda J Berberich; Robert A Hegele
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

Review 4.  Approach to the patient with extremely low HDL-cholesterol.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  J Clin Endocrinol Metab       Date:  2012-10       Impact factor: 5.958

5.  Unusual manifestation of monoclonal gammopathy of undetermined significance: a false serum creatinine elevation.

Authors:  Yoshinosuke Shimamura; Takuto Maeda; Yayoi Ogawa; Yuki Nagai; Toshiya Shinohara; Hideki Takizawa
Journal:  CEN Case Rep       Date:  2019-12-14

6.  A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia.

Authors:  Amir Shahbaz; Kashif Aziz; Muhammad Umair; Paria Zarghamravanbakhsh; Issac Sachmechi
Journal:  Cureus       Date:  2018-06-30

7.  Artifactual measurement of low serum HDL-cholesterol due to paraproteinemia.

Authors:  Edwin O F van Gorselen; Theo Diekman; Jan Hessels; Patrick M J Verhorst; Clemens von Birgelen
Journal:  Clin Res Cardiol       Date:  2010-07-01       Impact factor: 5.460

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.